Evidence map›Paper›PMID 38932408›Full record

ArticleVaccines2024

Assessing Predictive Value of SARS-CoV-2 Epitope-Specific CD8

Cristina Martín-Martín, Estefanía Salgado Del Riego, Jose R Vidal Castiñeira, Maria Soledad Zapico-Gonzalez, Mercedes Rodríguez-Pérez, Viviana Corte-Iglesias, Maria Laura Saiz, Paula Diaz-Bulnes, Dolores Escudero, Beatriz Suárez-Alvarez and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cristina Martín-MartínTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.
Estefanía Salgado Del RiegoService of Intensive Medicine, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.ORCID 0000-0003-4834-9263
Jose R Vidal CastiñeiraTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.
Maria Soledad Zapico-GonzalezMicrobiology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Mercedes Rodríguez-PérezMicrobiology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Viviana Corte-IglesiasTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.
Maria Laura SaizTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.
Paula Diaz-BulnesTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.
Dolores EscuderoService of Intensive Medicine, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Beatriz Suárez-AlvarezTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.
Carlos López-LarreaTranslational Immunology, Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011 Oviedo, Spain.

Funding

European Union through Next Generation EU funds, which support the actions of the Mecanismo de Recuperación y Resiliencia (MRR). IFEQ21/00203Instituto de Salud Carlos III (ISCIII) through projects co-funded by the European Union PI19/00184, PI20/00639 and PI22/00738PCTI-Plan de Ciencia, Tecnología e Innovación 2021-2023 from the Gobierno del Principado de Asturias Grant IDI/2021/000032
6 · The paper itself

Abstract

Specific T cell responses against SARS-CoV-2 provided an overview of acquired immunity during the pandemic. Anti-SARS-CoV-2 immunity determines the severity of acute illness, but also might be related to the possible persistence of symptoms (long COVID). We retrospectively analyzed ex vivo longitudinal CD8

Indexed as

epitope-specific CD8+ T cellhumoral responselong COVIDpHLA dextramersSARS-CoV-2vaccines

Identifiers

PMID38932408
PMCPMC11209605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.